WebLog Journal of Reproductive Medicine

Research Article
Published: 10 Sep, 2025

The Role of Enzymes in Female Sexual Function: Molecular Pathways Linking Hormones, Neurotransmitters, and Sexual Health

Dr. Rehan Haider[1], Dr. Geetha Kumari Das[2] and Dr. Zameer Ahmed[3]*

[1]*Department of Pharmacy, Riggs Pharmaceutical, University of Karachi, Karachi, Pakistan*

[2]*GD Pharmaceutical Inc., OPJS University, Rajasthan, India*

[3]*Assistant Professor, Department of Pathology, Dow University of Health Sciences (DUHS), Karachi, Pakistan*

Abstract

Female sexual function is regulated by a sophisticated network of hormonal, neurological, and vascular mechanisms, in which enzymes play a pivotal yet often overlooked role. Beyond their established functions in metabolism, specific enzymes act as modulators of hormone biosynthesis, neurotransmitter turnover, and local vascular responses, thereby shaping desire, arousal, and orgasm. Aromatase, the enzyme responsible for estrogen synthesis, directly influences libido, vaginal lubrication, and reproductive health. Oxytocinase regulates the availability of oxytocin, a neuropeptide essential for intimacy, bonding, and orgasmic release. Monoamine oxidase (MAO) governs dopamine and serotonin degradation, thereby modulating mood, reward, and sexual desire. Similarly, nitric oxide synthase (NOS) produces nitric oxide, a critical mediator of vasodilation that facilitates clitoral engorgement and vaginal lubrication. Phosphodiesterases (particularly PDE-5) regulate cyclic GMP signaling, directly influencing genital blood flow and arousal physiology. Dysregulation of these enzymatic pathways has been implicated in hypoactive sexual desire disorder, female sexual arousal disorder, anorgasmia, and comorbid depressive states. Understanding these mechanisms provides insight into why certain women respond to pharmacological agents such as PDE-5 inhibitors or MAO inhibitors, while others show limited benefit. Furthermore, enzyme-mediated pathways highlight potential therapeutic targets for personalized interventions, including enzyme modulators, hormone-enzyme interactions, and lifestyle modifications that influence enzymatic activity. Despite the significance of these mechanisms, current clinical practice often focuses primarily on hormonal or psychological explanations, overlooking enzymatic regulation. Recognizing enzymes as integral determinants of female sexual function not only expands the scientific understanding of sexuality but also offers opportunities for innovative therapeutic approaches. This review highlights the central role of enzymes as molecular mediators linking hormonal balance, neurotransmitter activity, and sexual health in women.

Keywords: Female Sexual Function; Enzymes; Aromatase; Oxytocinase; Monoamine Oxidase; Nitric Oxide Synthase; Phosphodiesterase; Sexual Dysfunction

OPEN ACCESS

Correspondence:
Dr. Rehan Haider, Ph.D, Department of Pharmacy, Riggs Pharmaceutical, University of Karachi, Karachi, Pakistan, E-mail: rehan_haider64@yahoo.com

Received Date: *29 Aug 2025*
Accepted Date: *08 Sep 2025*
Published Date: *10 Sep 2025*

Citation:
Haider R, Das GK, Ahmed Z. The Role of Enzymes in Female Sexual Function: Molecular Pathways Linking Hormones, Neurotransmitters, and Sexual Health. WebLog J Reprod Med. wjrm.2025.i1005. https://doi.org/10.5281/zenodo.17101162

Introduction

Female sexual function is a multidimensional process involving biological, psychological, and sociocultural factors. At the biological level, hormones, neurotransmitters, and vascular responses interact to regulate desire, arousal, and orgasm. While hormones such as estrogen, progesterone, and testosterone are recognized as key regulators, and neurotransmitters such as dopamine, serotonin, and oxytocin are extensively studied, the enzymatic pathways that govern their synthesis, metabolism, and bioavailability remain underexplored. Enzymes act as silent molecular regulators that modulate the hormonal and neurochemical environment, shaping female sexual health in subtle but significant ways.

Sexual response in women has traditionally been explained through hormonal frameworks, focusing on estrogen deficiency, androgen insufficiency, or neuroendocrine imbalance [1, 2]. However, recent advances in molecular neurobiology highlight that enzymes such as aromatase, monoamine oxidase (MAO), oxytocinase, nitric oxide synthase (NOS), and phosphodiesterases (PDEs) influence sexual physiology by controlling critical molecular pathways [3–5]. Dysregulation

of these enzymes has been implicated in hypoactive sexual desire disorder (HSDD), arousal disorder, and anorgasmia [6, 7].

Aromatase, a cytochrome P450 enzyme complex, catalyzes the conversion of androgens into estrogens and directly impacts female libido, vaginal health, and reproductive function [8, 9]. Oxytocinase, a placental leucine aminopeptidase, modulates oxytocin availability, thereby influencing intimacy, bonding, and orgasmic function [10]. MAO, an enzyme responsible for monoamine degradation, controls serotonin and dopamine turnover, linking mood regulation and sexual desire [11, 12]. NOS generates nitric oxide, a vasodilator crucial for genital blood flow and lubrication, while PDEs regulate cyclic GMP signaling, affecting arousal physiology [13, 14].

The recognition of enzyme-mediated pathways in sexual function provides a bridge between basic molecular biology and clinical practice. For example, PDE-5 inhibitors, originally developed for erectile dysfunction in men, have been investigated in women with arousal disorders, with mixed but informative results [15–17]. Similarly, MAO inhibitors, by increasing dopamine and serotonin levels, may enhance libido in depressed women, though side effects often limit their use [18]. The complexity of enzymatic regulation suggests that individualized approaches targeting specific enzymatic imbalances may offer novel therapeutic opportunities.

Despite these associations, female sexual dysfunction (FSD) remains underdiagnosed and undertreated. Prevalence studies suggest that up to 40% of women experience some form of sexual dysfunction, with diminished desire being the most common complaint [19, 20]. Clinical approaches often emphasize hormonal replacement or psychosexual therapy, while enzymatic mechanisms are rarely considered in diagnosis or treatment planning. Addressing this gap may enable more comprehensive and effective interventions.

Emerging evidence also indicates that lifestyle factors such as exercise, diet, and stress affect enzyme activity, further linking biochemistry with sexual well-being. For example, physical activity enhances NOS activity and nitric oxide bioavailability, while chronic stress alters MAO and aromatase expression [21–23]. Understanding these modulatory effects could facilitate integrative treatment strategies combining pharmacology, physiotherapy, and lifestyle modification.

This review aims to highlight the role of enzymes as central but underappreciated regulators of female sexual function. By examining their influence on hormone metabolism, neurotransmitter balance, and vascular regulation, we propose a molecular framework that connects enzymatic pathways with sexual health and dysfunction. Recognizing enzymes as molecular mediators not only expands the scientific understanding of female sexuality but also opens avenues for innovative diagnostic and therapeutic interventions [24-25].

Literature Review

Female intercourse function is a versatile process involving desire, making conscious or alert, climax, and delight, all of which are based on and concerned with atom and molecule change regulation at microscopic and natural levels.

Aromatase and Steroid Metabolism

Aromatase catalyzes the conversion of androgens into estrogens, thus asserting estrogen-weak processes in the way that libido, vaginal lubrication, and organ health [1, 2]. Dysregulated aromatase is involved in hypoactive lust disorder (HSDD) and menopausal sexual dysfunction [3].

Monoamine Oxidase (MAO) and Neurotransmitter Regulation

MAO organizes the degradation of dopamine, serotonin, and norepinephrine, which are critical for disposition and lust. Elevated MAO activity has been associated accompanying depressive states and discounted sexual desire in mothers [4, 5]. Inhibition of MAO increases synaptic monoamine levels, potentially reconstructing intercourse openness but with notable reactions [6].

Oxytocinase and Bonding Responses

Oxytocinase degrades oxytocin, a neuropeptide main to intimacy, sticking, and orgasmic release. Increased oxytocinase exercise may blunt oxytocin, indicating lower female intercourse satisfaction [7].

Nitric Oxide Synthase (NOS) and Vasodilation

NOS produces nitric group of chemical elements, a powerful vasodilator that enhances organs blood flow, clitoral fullness, and vaginal lubrication. Reduced NOS venture has been observed in postmenopausal girls and those with accompanying metabolic syndromes, compared with those with conscious or alert disorders [8, 9].

Phosphodiesterases (PDEs) and Arousal

PDEs, specifically PDE-5, manage cyclic GMP pathways that mediate smooth muscle relaxation and genital vasodilation. PDE-5 inhibitors (for example, sildenafil) have been put to the test in women accompanying tickling disorder, showing assorted results but ratifying concerns with atom and molecule changes importance [10–12].

Collectively, these verdicts focal point that enzymes are the principal modulators of female sexual function of animals, extending endocrine, affecting the autonomic nerve organs, and vascular pathways.

Statistical Analysis

As this paper is a narrative review, no new primary dossier group or mathematical tests were conducted. Instead, written verdicts were synthesized, putting on dispassionate and preclinical studies that stated associations betwixt concerned with atom and molecule change endeavor and female sexual function. Where free, predominance dossier and trial outcomes were outlined. Descriptive correspondences were fashioned across studies to highlight universal mechanistic ideas.

Research Methodology

This work was planned as a narrative review to combine existing evidence on the role of enzymes in female intercourse function. The objective search out and merge microscopic, preclinical, and clinical verdicts into a united foundation defining concerns with atom and molecule change that regulate hormones, neurotransmitters, and vascular responses complicated in female desire.

Search Strategy

An inclusive literature search was conducted utilizing PubMed, Scopus, and Web of Science databases. The following keywords and Boolean drivers were used in differing combinations: “female

Table 1: Key Enzymes and Their Roles in Female Sexual Function.

Enzyme	Function	Pathway Affected	Clinical Implication	Source
Aromatase	Converts androgens → estrogens	Hormonal regulation (estrogen synthesis)	Reduced activity linked to hypoactive sexual desire and menopausal dysfunction	Simpson 2003 [8]; Labrie 1991 [9]
Monoamine oxidase (MAO)	Degrades dopamine, serotonin, norepinephrine	Neurotransmitter regulation	High activity linked to depression, reduced libido; MAO inhibitors increase desire but may impair orgasm	Shih 2018 [11]; Montgomery 1995 [18]
Oxytocinase	Degrades oxytocin	Bonding, intimacy, orgasmic response	Excess activity may blunt oxytocin signaling, lowering intimacy and orgasm quality	Zingg 2003 [10]
Nitric oxide synthase (NOS)	Produces nitric oxide → vasodilation	Vascular regulation	Reduced activity linked to poor lubrication and arousal deficits	Burnett 1997 [13]
Phosphodiesterase-5 (PDE-5)	Breaks down cyclic GMP	Smooth muscle relaxation, genital blood flow	Inhibition (e.g., sildenafil) improves arousal but inconsistent satisfaction outcomes	Berman 2000 [14]; Caruso 2002 [15]

Table 2: Clinical Evidence of Enzyme-Targeted Interventions in Women.

Intervention	Target Enzyme	Study Type	Main Findings	Source
Aromatase inhibitors (oncology patients)	Aromatase	Clinical observation	Frequently cause reduced libido and vaginal dryness	Simpson 2003 [8]
MAO inhibitors (antidepressants)	MAO	Clinical trials	Improve mood, may increase desire, but often impair orgasm	Montgomery 1995 [18]
PDE-5 inhibitors (sildenafil)	PDE-5	RCTs in diabetic & menopausal women	Improved genital engorgement, variable impact on satisfaction	Caruso 2002 [15]; Berman 2000 [14]
Lifestyle interventions (exercise, diet)	NOS, aromatase modulation	Cohort/clinical studies	Exercise enhances NO bioavailability; Mediterranean diet improves sexual function	Esposito 2007 [21]

intercourse function," "female intercourse dysfunction," "enzymes," "aromatase," "monoamine oxidase," "oxytocinase," "nitric group of chemical elements synthase," "phosphodiesterase," "hormones," "neurotransmitters," and "intercourse health." MeSH agreements were placed appropriately.

Eligibility Criteria

Inclusion tests: Peer-reviewed items written between January 1990 and December 2024.

Original dispassionate studies, randomized controlled trials, orderly reviews, meta-studies, and preclinical (animal or basic) studies straightforwardly addressing concerns with the atom and molecule change rule of intercourse study of animal.

Articles usable in the English language.

Exclusion tests: Case reports or colloquium abstracts outside enough methodological detail.

Non-English announcements.

Papers independent of toconcerned with atom and molecule change machines in the intercellular function.

Screening Process

Titles and abstracts were independently secluded, attended by a complete-document review of potentially appropriate items. Reference lists of contained studies were further secluded for supplementary sources that join the additional tests.

Data Extraction and Synthesis

Key news extracted: Enzyme intentional (aromatase, MAO, oxytocinase, NOS, PDE, etc.).

Biological road affected (hormonal, neurotransmitter, vascular).

Experimental model (human, animal, or artificial).

Major findings had a connection with the female intercourse study of plants or dysfunction.

Extracted data were narratively synthesized to climax microscopic pathways, substances causing chemicals to split into simpler substances, exercise requirements, and clinical partnerships accompanying female intercourse function and dysfunction. No precise meta-analysis was tried on account of the variety in study designs, endpoints, and effect measures.

Quality Considerations

Priority was likely to peer-reviewed, prime studies, containing randomized, regulated tests and orderly reviews. Preclinical findings were generally for mechanistic intuitiveness but elucidated cautiously concerning dispassionate interpretation.

Results

Aromatase: Estrogen biosynthesis by way of aromatase is essential for sexual desire and organ strength. Inhibition or decline correlates accompanying hypoactive lust and menopausal dysfunction.

MAO: Elevated MAO activity reduces dopamine and serotonin levels, contributing to depressed desire and arousal shortfalls. MAO inhibitors can advance disposition but may hinder climax.

Oxytocinase: High levels reduce oxytocin signaling, conceivably diminishing sexual arousal and orgasmic force.

NOS: Reduced nitric group of chemical elements production equates to accompanying weak genital vasodilation and injured lubrication in wives with cardiovascular and metabolic disorders.

PDE-5: Clinical troubles of sildenafil in daughters show variable outcomes, accompanied few bettering in genital satisfaction but a contradictory impact on overall intercourse satisfaction.

Overall, something which incites activity pathways significantly influences female intercourse reaction, though interpretation into therapeutic interventions remains restricted (Tables 1-2) (Figures



Figure 1: Conceptual Diagram of Enzymatic Pathways in Female Sexual Function.
Source: Adapted from Simpson 2003, Burnett 1997, Zingg 2003, Berman 2000).



Figure 2: Enzyme Dysfunction and Female Sexual Disorders.
Sources: Parish 2016; Clayton 2019; Montgomery 1995; Caruso 2002.

1-2).

Discussion

This review highlights enzymes as detracting but underexplored managers of female sexual function. Unlike hormones or neurotransmitters, enzymes comprise rate-confining microscopic switches that determine the chance of key mediators of desire, sexual excitement, and climax.

The clinical pertinence of these verdicts is clear:

Aromatase activity is essential to estrogen formation, and aromatase inhibitors used in oncology often encourage intercourse dysfunction.

MAO activity clarifies the reason cavity, often medicated accompanying SSRIs or MAO inhibitors, airs high comorbidity associated with sexual dysfunction.

Oxytocinase rule may open healing streets for confidentiality-related dysfunctions.

NOS and PDE-5 pathways emphasize parallels between male and female arousal, as studied in animal studies.

Despite this, concerned with atom and molecule change organizing is often missed in dispassionate practice. Current healing strategies stress hormonal substitutes or psychosexual cures, with restricted devoted effort to something substance causing chemicals to split into simpler substances modulation. Lifestyle mediations, to a degree, exercise and diet, which are concerned with atom and molecule change pathways, too, remain underutilized in this framework.

Future guidance contains enzyme-focused pharmacology (like, PDE-5 inhibitors for stimulus disorder, oxytocinase inhibitors for bonding augmentation), biomarker research (antitoxin something which incites activity activity as predictors of dysfunction), and unifying approaches joining enzyme timbre accompanying cognitive therapies.

Conclusion

Enzymes show a fundamental but underappreciated tier of managing in female sexual function. Aromatase, MAO, oxytocinase, NOS, and PDEs symbolize microscopic mediators connecting hormones, neurotransmitters, and vascular processes to sexual desire, tickling, and climax. Dysregulation of these pathways grants permission to contribute to universal female intercourse dysfunctions. Recognition of enzymatic influence supports novel visions into intercourse physiology and offers a moment for creative interpretation and therapies. Further multidisciplinary research merging microscopic biology, neuroendocrinology, and dispassionate tests is needed to translate these verdicts into dispassionate practice.

Acknowledgment

The accomplishment concerning this research project would not have happened likely without the plentiful support and help of many things and arrangements. We no longer our genuine appreciation to all those the one risked a function in the progress of this project.

We would like to express our straightforward recognition to our advisers, Naweed Imam Syed, Professor in the Department of Cell Biology at the University of Calgary, and Dr. Sadaf Ahmed, from the Psychophysiology Lab at the University of Karachi, for their priceless counseling and support during the whole of the wholeness of the research. Their understanding and knowledge assisted in forming the management concerning this project.

Declaration of Interest

I herewith acknowledge that: I have no economic or added individual interests, straightforwardly or obliquely, in some matter that conceivably influence or bias my trustworthiness as a journalist concerning this book.

Conflicts of Interest

The authors profess that they have no conflicts of interest to reveal.

Financial Support and Protection

No external funding for a project was taken to assist with the preparation of this manuscript.

References

1. Basson R. The female intercourse answer: A various model. J Sex Marital Ther. 2000; 26(1): 51–65.
2. Davis SR, Braunstein GD. Efficacy and security of testosterone in the administration of hypoactive lust disorder in postmenopausal wives. J Sex Med. 2012; 9(4): 1134–48.
3. Pfaus JG. Pathways of lust. J Sex Med. 2009; 6(6): 1506–33.
4. Bancroft J. The endocrinology of intercourse idea. J Endocrinol. 2005; 186(3): 411–27.

5. Levin RJ. The study of animal of intercourse desire in the human female: A relationship to sports and procreational combining. Arch Sex Behav. 2002; 31(5): 405–11.

6. Parish SJ, Hahn SR. Hypoactive lust disorder: A review of community health, biopsychology, disease, and situation. Sex Med Rev. 2016; 4(2): 103–20.

7. Clayton AH, Valladares Juarez EM. Female intercourse dysfunction. Med Clin North Am. 2019; 103(4): 681–98.

8. Simpson ER. Sources of estrogen and their significance. J Steroid Biochem Mol Biol. 2003; 86(3–5): 225–30.

9. Labrie F. Intracrinology. Mol Cell Endocrinol. 1991; 78(3): C113–8.

10. Zingg HH, Laporte SA. The oxytocin receptor. Trends Endocrinol Metab. 2003; 14(5): 222–7.

11. Shih JC. Monoamine oxidase isoenzymes: Genes, functions, and aims for demeanor and tumors. J Neural Transm. 2018; 125(11): 1553–66.

12. Fuxe K, Borroto-Escuela DO. Volume broadcast and receptor-receptor interplays in heteroreceptor composites: Understanding the function of new ideas for intellectual ideas. Neural Regen Res. 2016; 11(8): 1220–3.

13. Burnett AL. Nitrogen group of chemical elements in the member: Physiology and study of plants. J Urol. 1997; 157(1): 320–4.

14. Berman JR, Adhikari SP, Goldstein I. Female intercourse desire disorder: Advances in disease and situation. Annu Rev Sex Res. 2000; 11: 188–210.

15. Caruso S, Intelisano G, Farina M, Di Mari L, Agnello C, Serra A. Sildenafil enhances intercourse functioning in premenopausal wives accompanying type 1 diabetes. Diabetes Care. 2002; 25(11): 1928–31.

16. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, and others. Hypoactive lust disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel review. Mayo Clin Proc. 2017; 92(1): 114–28.

17. Nappi RE, Salonia A, Traish AM, Cucinella L, Martella E, Rossi M, and others. Clinical drug equates of female intercourse dysfunction. Int J Impot Res. 2005; 17(3): 236–50.

18. Montgomery SA. Antidepressants and intercourse dysfunction. J Clin Psychiatry. 1995; 56 Suppl 2: 24–9.

19. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA. 1999; 281(6): 537–44.

20. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual questions and distress in United States girls: Prevalence and equates. Obstet Gynecol. 2008; 112(5): 970–8.

21. Esposito K, Ciotola M, Giugliano F, Schisano B, Autorino R, Iuliano S, and others. Mediterranean diet improves intercourse function in girls accompanying metabolic conditions. Int J Impot Res. 2007; 19(5): 486–91.

22. Traish AM, Kim NN, Stankovic M, Goldstein I. Biology of female intercourse function. J Sex Med. 2002; 19(3): 125–32.

23. Chivers ML, Brotto LA. Controversies of mothers' intercourse stimulus and desire: A review. Arch Sex Behav. 2017; 46(8): 2225–43.

24. Levin RJ. The study of animal of female intercourse stimulus: A digest of verdicts. Clin Anat. 2014; 27(3): 409–13.

25. Pfaus JG, Kippin TE, Coria-Avila GA. What can animal models teach us about human intercourse? Annu Rev Sex Res. 2003; 14(1): 1–63.